Treatment of Clostridium difficile Infection with a Small-Molecule Inhibitor of Toxin UDP-Glucose Hydrolysis Activity

Identification and initial optimization of inhibitors of Clostridium difficile ( C. difficile ) toxin B (TcdB)

(2018) Jeffrey J. Letourneau et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection

(2017) Mark H. Wilcox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost of hospital management of Clostridium difficile infection in United States—a meta-analysis and modelling study

(2016) Shanshan Zhang et al.   BMC INFECTIOUS DISEASES

New and emerging therapies for Clostridium difficile infection

(2016) Jessica Martin et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Burden of Clostridium difficile Infection in the United States

(2015) Fernanda C. Lessa et al.   NEW ENGLAND JOURNAL OF MEDICINE

A small-molecule antivirulence agent for treating Clostridium difficile infection

(2015) Kristina Oresic Bender et al.   Science Translational Medicine

Toxin-Mediated Paracellular Transport of Antitoxin Antibodies Facilitates Protection against Clostridium difficile Infection

(2014) Z. Zhang et al.   INFECTION AND IMMUNITY

Critical Roles of Clostridium difficile Toxin B Enzymatic Activities in Pathogenesis

(2014) Shan Li et al.   INFECTION AND IMMUNITY

Variations in Virulence and Molecular Biology among Emerging Strains of Clostridium difficile

(2013) J. J. Hunt et al.   MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS

A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile

(2013) R. G. K. Donald et al.   MICROBIOLOGY-SGM

The structure ofClostridium difficiletoxin A glucosyltransferase domain bound to Mn2+and UDP provides insights into glucosyltransferase activity and product release

(2012) Nunzia D’Urzo et al.   FEBS Journal

Intrarectal Instillation of Clostridium difficile Toxin A Triggers Colonic Inflammation and Tissue Damage: Development of a Novel and Efficient Mouse Model of Clostridium difficile Toxin Exposure

(2012) Simon A. Hirota et al.   INFECTION AND IMMUNITY

Host S-nitrosylation inhibits clostridial small molecule–activated glucosylating toxins

(2011) Tor C Savidge et al.   NATURE MEDICINE

Defining an allosteric circuit in the cysteine protease domain of Clostridium difficile toxins

(2011) Aimee Shen et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Fidaxomicin versus Vancomycin forClostridium difficileInfection

(2011) Thomas J. Louie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dali server: conservation mapping in 3D

(2010) Liisa Holm et al.   NUCLEIC ACIDS RESEARCH

Tolevamer Is Not Efficacious in the Neutralization of Cytotoxin in a Human Gut Model of Clostridium difficile Infection

(2009) S. D. Baines et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Structure-Function Analysis of Inositol Hexakisphosphate-induced Autoprocessing inClostridium difficileToxin A

(2009) Rory N. Pruitt et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Clostridium difficile infection: new developments in epidemiology and pathogenesis

(2009) Maja Rupnik et al.   NATURE REVIEWS MICROBIOLOGY

Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI)

(2009) Brett A. Leav et al.   VACCINE

A Mouse Model of Clostridium difficile–Associated Disease

(2008) Xinhua Chen et al.   GASTROENTEROLOGY

Decreased Diversity of the Fecal Microbiome in RecurrentClostridium difficile–Associated Diarrhea

(2008) Ju Young Chang et al.   JOURNAL OF INFECTIOUS DISEASES

Structure and mode of action of clostridial glucosylating toxins: the ABCD model

(2008) Thomas Jank et al.   TRENDS IN MICROBIOLOGY